✦ LIBER ✦

Safety and efficacy of everolimus (RAD) as part of a triple immunosuppressive regimen in de novo cardiac transplant recipients: six-month analysis

✍ Scribed by H. Eisen; R. Dorent; D. Mancini; H. Valantine; M. Vigano; R. Starling; J. Lind; P. Bernhardt; K. Abeywickrama

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

695: Rapid Achievement of Therapeutic Le

✍ U. Livi; J. Arizon; M.-F. Mattei; F. Musumeci; M. Maccherini; L. Almenar; J. Del 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 203 KB

Comparison of an Innovative Everolimus-C

✍ Gottlieb, J.; Deuse, T.; Witt, C.; Neurohr, C.; Mueller-Quernheim, J.; Sommerwer 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 159 KB

26 EVEROLIMUS-BASED IMMUNOSUPPRESSION PR

✍ Nevens, F.; De Carlis, L.; Metselaar, H.J.; Kaiser, G.M.; Saliba, F.; Jonas, S.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Efficacy and safety of de novo or early

✍ Jacques Dantal; François Berthoux; Marie-Christine Moal; Lionel Rostaing; Christ 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 335 KB

A 12-month, multicenter, randomized, ada

✍ H. Ross; M. Cantarovich; J. Arizon; J. Orus; L. Straatman; J. Howlett; E. Lage; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Six month data of a 12-month, single-bli

✍ J.A Kobashigawa; S.F Davis; D.G Renlund; M Hummel; G Gerosa; R Brambilla 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 85 KB